Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development
Последние достижения в биопроцессинге рекомбинантных белков: системы экспрессии и разработка процессов
2019-12-19
SCID: 54.1/2h2usrjn
Discuss with AI
Quality by Designbioprocess optimizationcontinuous bioprocessingexpression host systemsrecombinant proteins
Figures from the paper
Abstract (AI)
Infectious diseases, along with cancers, are among the main causes of death among humans worldwide. The production of therapeutic proteins for treating diseases at large scale for millions of individuals is one of the essential needs of mankind. Recent progress in the area of recombinant DNA technologies has paved the way to producing recombinant proteins that can be used as therapeutics, vaccines, and diagnostic reagents. Recombinant proteins for these applications are mainly produced using prokaryotic and eukaryotic expression host systems such as mammalian cells, bacteria, yeast, insect cells, and transgenic plants at laboratory scale as well as in large-scale settings. The development of efficient bioprocessing strategies is crucial for industrial production of recombinant proteins of therapeutic and prophylactic importance. Recently, advances have been made in the various areas of bioprocessing and are being utilized to develop effective processes for producing recombinant proteins. These include the use of high-throughput devices for effective bioprocess optimization and of disposable systems, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, Quality by Design, and process analytical technologies to achieve quality product with higher yield. This review summarizes recent developments in the bioprocessing of recombinant proteins, including in various expression systems, bioprocess development, and the upstream and downstream processing of recombinant proteins.
Key Findings
1
Disposable systems, continuous upstream processing, continuous chromatography, and integrated continuous processing support higher-yield production of quality products.
2
High-throughput devices enable more effective optimization of recombinant-protein bioprocesses.
3
Quality by Design and process analytical technologies are being applied to ensure product quality during recombinant-protein manufacturing.
4
Recent bioprocessing advances aim to improve the industrial production of therapeutic, prophylactic, and diagnostic recombinant proteins.
5
Recombinant proteins are produced at laboratory and industrial scales using mammalian, bacterial, yeast, insect-cell, and transgenic-plant expression systems.
Research Object
recombinant proteins produced in prokaryotic and eukaryotic expression host systems
Research Subject
bioprocessing strategies and upstream and downstream process development for producing recombinant proteins with improved quality and yield
Publication Details
Publication Date
2019-12-19
Journal
Publisher
ISSN
Cited by
620
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai6
Recombinant protein expression in Escherichia coli: advances and challenges2014
Microbial factories for recombinant pharmaceuticals2009
Therapeutic glycoprotein production in mammalian cells2017
Perfusion mammalian cell culture for recombinant protein manufacturing – A critical review2018
Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells2013
Evaluation of scFv protein recovery from E. coli by in vitro refolding and mild solubilization process2019
Cited by3
Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review2024
Recombinant expression of insoluble enzymes in Escherichia coli: a systematic review of experimental design and its manufacturing implications2021
Understanding the effect of temperature downshift on CHO cell growth, antibody titer and product quality by intracellular metabolite profiling and in vivo monitoring of redox state2023